Merck turns up heat: immunotherapy trio of deals disclosed
Merck & Co. Inc.’s minor slip in its latest earnings wrap-up was offset by news of three separately done deals to combine the company’s prized immunotherapy MK-3475 in various phase I/II trials with cancer drugs from Amgen Inc., Incyte Corp. and Pfizer Inc. – arrangements intended to help Merck gain ground against the likes of Bristol-Myers Squibb Co. (BMS) in the anti-PD-1 space by getting access to unpartnered cancer assets by way of research pacts.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST